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Abstract
Background: Lung infection by various organisms is a characteristic feature of cystic fibrosis (CF). CFTR genotype
effects acquisition of Pseudomonas aeruginosa (Pa), however the effect on acquisition of other infectious organisms
that frequently precede Pa is relatively unknown. Understanding the role of CFTR in the acquisition of organisms
first detected in patients may help guide symptomatic and molecular-based treatment for CF.
Methods: Lung infection, defined as a single positive respiratory tract culture, was assessed for 13 organisms in
1,381 individuals with CF. Subjects were divided by predicted CFTR function: ‘Residual’: carrying at least one partial
function CFTR mutation (class IV or V) and ‘Minimal’ those who do not carry a partial function mutation. Kaplan-
Meier estimates were created to assess CFTR effect on age of acquisition for each organism. Cox proportional
hazard models were performed to control for possible cofactors. A separate Cox regression was used to determine
whether defining infection with Pa, mucoid Pa or Aspergillus (Asp) using alternative criteria affected the results. The
influence of severity of lung disease at the time of acquisition was evaluated using stratified Cox regression
methods by lung disease categories.
Results: Subjects with ‘Minimal’ CFTR function had a higher hazard than patients with ‘Residual’ function for
acquisition of 9 of 13 organisms studied (HR ranging from 1.7 to 3.78 based on the organism studied). Subjects
with minimal CFTR function acquired infection at a younger age than those with residual function for 12 of 13
organisms (p-values ranging: < 0.001 to 0.017). Minimal CFTR function also associated with younger age of
infection when 3 alternative definitions of infection with Pa, mucoid Pa or Asp were employed. Risk of infection is
correlated with CFTR function for 8 of 9 organisms in patients with good lung function (>90%ile) but only 1 of 9
organisms in those with poorer lung function (<50%ile).
Conclusions: Residual CFTR function correlates with later onset of respiratory tract infection by a wide spectrum of
organisms frequently cultured from CF patients. The protective effect conferred by residual CFTR function is
diminished in CF patients with more advanced lung disease.
Background
Cystic fibrosis (CF) is the most common autosomal
recessive life-shortening disorder in the Caucasian popu-
lation and progressive obstructive lung disease is the
primary cause of mortality [1,2]. Persistent respiratory
infection by particular organisms, such as Pseudomonas
aeruginosa (Pa) and Burkholderia cepacia complex
(Bcc), are hallmarks of CF lung disease and lead to the
progressive obstructive lung disease [2-5]. Infection with
Pa is often preceded by infection with other organisms
that are rarely cultured from healthy individuals such as
Staphylococcus aureus. Additionally, a number of other
pathogens such as methicillin resistant Staphylococcus
aureus (MRSA) [6], Achromobacter xylosoxidans (Ax)
[7] and Aspergillus fumigatus (Asp) [8] have been found
to infect CF patients and affect the severity of lung
* Correspondence: gcutting@jhmi.edu
3McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University
School of Medicine, Baltimore, MD, USA
Full list of author information is available at the end of the article
Green et al. Respiratory Research 2010, 11:140
http://respiratory-research.com/content/11/1/140
© 2010 Green et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
disease in these patients. Mutations which permit resi-
dual CFTR function and confer a “mild” phenotypic
effect have been associated with lower rates of Pa infec-
tion [9,10]. However, it is not clear whether residual
CFTR function also influences acquisition of respiratory
pathogens other than Pa [11].
Teasing out the role that CFTR genotype has on CF
lung infection is important for several reasons. Recent
success in the identification of small molecules aug-
menting CFTR function raises the possibility that delay
of infection might be used as a measure for clinical effi-
cacy of these new treatments, especially in children
where few alternative options exist [12]. Secondly,
patient populations have been accrued to find genetic
modifiers of traits such as risk of infection and quantify-
ing the contribution CFTR has to infection aids the
search for genetic modifiers of this trait providing novel
therapeutic targets for CF. Finally, neonatal CF pigs
show acquisition of infection with a variety of organisms
indicating that loss of CFTR function causes a pervasive
defect in lung defense [13]. If this is the case in humans,
then alteration in CFTR function should correlate with
infection with a variety of respiratory pathogens. To
address these issues, we evaluated the correlation
between CFTR genotype and infection with a variety of
pathogens using detailed infection data collected by the
U.S. CF Twin and Sibling Study (CFTSS) [14].
Methods
Population
All subjects in the U.S. CFTSS were recruited on the
basis of having a twin or sibling affected with CF. All
enrolled patients met CF diagnostic criteria [15] and
99% attend CF care centers in the United States. Isola-
tion of patient DNA, identification of CFTR mutations,
and zygosity testing have been previously described
[14,16]. Written, informed consent/assent was obtained
from all subjects and/or their guardians, and this study
was approved by the Johns Hopkins University Institu-
tional Review Board.
Definitions of infection
Thirteen organisms were studied including Pseudomonas
aeruginosa (Pa), mucoid Pa (MPa), Staphylococcus aur-
eus (Sa), Methicillin resistant Sa (MRSa), Burkholderia
cepacia complex (Bcc), Atypical mycobacteria (atyp),
Aspergillus fumigatus (Asp), Stenotrophomonas maltophi-
lia (Sm), Achromobacter xylosoxidans (Ax), Haemophilus
influenzae (Hi), Streptococcus pneumoniae (Sp), Escheri-
chia coli (Ec), and Klebsiella pneumoniae (Kp). Subjects
were defined as having an “infection” with the organism
in question if they had a positive oropharyngeal culture
(throat, sputum, or bronchoalveolar lavage culture) for
that particular organism (FirstInfx), regardless of whether
the subject was positive for other organisms. An addi-
tional inclusion criterion was that a negative culture for
the organism had to have been obtained a minimum of
one week prior to the first positive culture to insure that
subjects were in follow-up and routine cultures were
being obtained. Patients treated at CF care centers in the
U.S. have complete microbiological assessment of
respiratory cultures at least annually and preferably quar-
terly. All subjects were passively followed-up after enroll-
ment in the CFTSS until December 31, 2008 with culture
data provided from their care centers and the CF Foun-
dation Patient registry. Subjects were excluded if a
respiratory culture was never performed prior to Decem-
ber 31, 2008.
A separate analysis of infection with Pa, MPa and Asp
was performed using 3 additional criteria to define
infection: 1) chronic infection (ChronInfx): 3 positive
cultures within 6 months with each culture separated by
at least 1 month (similar to that employed in Europe)
[17] 2) multiple infection (MultiInfx): at least 3 positive
cultures, but not meeting the definition for ChronInfx
(as most patients in the U.S. do not attend CF clinic 3
times in 6 months); and 3) persistently infected (Per-
sInfx): multiple cultures obtained in 3 consecutive years
with positive cultures observed in at least 2 of the
3 years (recently used in a CF modifier study [18]).
CFTR genotypes and other variables
Subjects were grouped according to the functional class
of CFTR mutations that he/she carried [10,19-22]
(TABLE 1). Lung function variables were created using
the maximum FEV1 within the year preceding the date
of the first positive culture for a given organism refer-
enced against the CF population (Kulich CF specific
FEV1 percentile) [23] (FEV1BeforeInfx). The number of
cultures per year for the subject was determined as the
number of respiratory cultures obtained from the sub-
ject divided by the time (in years) from first documented
culture to the last recorded culture (cultures per year).
Age of acquisition was defined as the time from birth
until recorded first positive culture for a given organism.
Subjects who did not have a positive culture for the
organism were assigned their age at the last obtained
culture.
Statistical analysis and regression modeling
Time to acquisition of the first positive culture for an
organism was assessed by the Kaplan Meier product limit
estimator and the log-rank test. Cox proportional hazard
regression models were used to account for covariates
which could affect the relationship of CFTR genotype
and age of acquisition for a particular organism. Covari-
ates were identified a priori based on clinical experience
and review of literature. Univariate regression was first
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performed with co-variates of gender (male vs. female),
ethnicity (Caucasian vs. non-Caucasian), pancreatic sta-
tus (pancreatic insufficient vs. pancreatic sufficient),
FEV1BeforeInfx (linear co-variate), and cultures per year
(linear co-variate) to identify significant co-variates.
Co-variates with a p-value < 0.05 (pancreatic status,
FEV1BeforeInfx, and cultures per year) were included in
a multivariate Cox regression. In this regression, only
FEV1BeforeInfx and cultures per year remained signifi-
cant with p-values < 0.05. The final multivariate Cox
regression model included FEV1BeforeInfx for the organ-
ism and cultures per year.
A second analysis was performed also using Cox
regression to assess the relationship of CFTR with alter-
native ways of defining infection status for Pa, MPa and
Asp. This regression was also adjusted for FEV1Befor-
eInfx for the organism and cultures per year. The time
to “event” was defined as the age of the subject from
birth until the first positive culture that would be
included to meet the infection definition. In other
words, for a subject meeting the definition of ChronInfx,
the subject would need 3 positive cultures within 6
months but each 1 month from the other and the age of
the subject at the first of the 3 positive cultures would
be used. If subjects did not meet the definition of infec-
tion the age at the last obtained culture is used for cen-
soring. All statistical calculations were performed using
Intercooled Stata 10 (Stata Corp., College Station, TX).
Results
Clinical characteristics and infection rates in the study
population
1,659 CF patients were enrolled in the U.S. CFTSS as of
December 31, 2008. Thirty-five subjects were excluded
for lack of infection data; 16 for lack of CFTR genotype
information; 227 subjects for inability to classify CFTR
mutations. The remaining 1,381 subjects were stratified
according to predicted mutation effect upon CFTR
function. ‘Residual’ function was defined as the presence
of at least one class IV or V mutation (n = 163) while
‘Minimal’ function was defined as presence of only class
I, II or III mutations (n = 1218). As expected from pre-
vious reports [10,11] subjects grouped according to pre-
dicted CFTR function differed for multiple characteristics
(TABLE 2). Prevalence data for the organisms studied as
well as comparability of the study sample to the general
U.S. CF population is available in TABLE 3.
Residual CFTR function decreases the risk of respiratory
infection by multiple organisms
Kaplan Meier analysis was performed to assess the effect
of CFTR genotype upon the age at which the infection
was acquired for 13 organisms. The unadjusted median
age of acquisition for Pa for subjects with ‘Minimal’
CFTR function was substantially lower (5.5 years) than
those with ‘Residual’ CFTR function (14.5 years; log
rank p-value: < 0.001). Overall prevalence of Asp in this
study was less than 50%, we report the age at which
25% of the population would be affected. Patients with
‘Minimal’ function reached 25% prevalence at11.3 years
while those with ‘Residual’ function reached this rate at
19.8 years (p-value < 0.001). Ten other organisms also
had a lower age of acquisition in those subjects with
‘Minimal’ CFTR function when compared to ‘Residual’
function using log rank tests. (See FIGURE 1 for further
details).
As noted in TABLE 2, subjects with ‘Residual’ CFTR
function and those with ‘Minimal’ CFTR function differ
in a number of respects, therefore a Cox proportional
hazards model was created that incorporated these dif-
ference as covariates. The final multivariate Cox regres-
sion included lung function (FEV1BeforeInfx) and
cultures per year. Nine of the 13 organisms were found
to have a significant hazard ratio (HR) indicating an
increased risk of acquisition in subjects with ‘Minimal’
CFTR function (FIGURE 1). For Pa, the hazard ratio
Table 1 Classification of CFTR alleles
Category Mutation Specific mutations
Class I Defective Protein Synthesis (nonsense,
frameshift, aberrant splicing)
1078delT, 1154 insTC, 1525-2A > G, 1717-1G > A, 1898+1G > A, 2184delA, 2184 insA,
3007delG, 3120+1G > A, 3659delC, 3876delA, 3905insT, 394delTT, 4010del4, 4016insT,
4326delTC, 4374+1G > T, 441delA, 556delA, 621+1G > T, 621-1G > T, 711+1G > T, 875+1G >
C, E1104X, E585X, E60X, E822X, G542X, G551D/R553X, Q493X, Q552X, Q814X, R1066C, R1162X,
R553X, V520F, W1282X, Y1092X
Class II Abnormal Processing and Trafficking A559T, D979A, ΔF508, ΔI507, G480C, G85E, N1303K, S549I, S549N, S549R
Class III Defective Channel Regulation/Gating G1244E, G1349D, G551D, G551S, G85E, H199R, I1072T, I48T, L1077P, R560T, S1255P, S549
(R75Q)
Class IV Decreased Channel Conductance A800G, D1152H, D1154G, D614G, delM1140, E822K, G314E, G576A, G622D, G85E, H620Q,
I1139V, I1234V, L1335P, M1137V, P67L, R117C, R117P, R117H, R334W, R347H, R347P, R347P/
R347H, R792G, S1251N, V232D
Class V Reduced Synthesis and/or Trafficking 2789+5G > A, 3120G > A, 3272-26A > G, 3849+10kbC > T, 5T variant, 621+3A > G, 711+3A >
G, A445E, A455E, IVS8 poly T, P574H
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was increased 3 fold for those with ‘Minimal’ function
when compared to those with ‘Residual’ function.
Increased risk for the other 8 organisms ranged from
1.7 to 3.8. Bcc is not presented in the figure as it was
found to not be associated with CFTR genotype by log
rank or Cox regression.
Residual CFTR function decreases risk of infection with
Pa, MPa and Asp regardless of infection definition
Various criteria have been employed in the literature to
define infection status [17]. As this study is retrospective
and possibly prone to misclassification, we determined
whether the use of different criteria with more rigorous
definitions for infection altered the results. Patients were
classified for infection status for Pa, MPa and Asp using
three other definitions (ChronInfx, MultiInfx and Per-
sInfx). The number of subjects defined as positive using
each definition is presented in TABLE 4. One-hundred
nineteen subjects were positive for Pa by all 4 methods.
Forty-one subjects were positive by 2 of 4 definitions,
most commonly meeting the definition of FirstInfx and
MultiInfx. Only 55 subjects were positive by the defini-
tion for FirstInfx. Similar concordance was found for
MPa with 180 subjects positive using all 4 definitions
and 78 only positive for FirstInfx. For Asp, fewer sub-
jects were positive for all four definitions (n = 76) and
140 were only positive if FirstInfx was used to define
infection.
Multivariate Cox regression was used to assess the
relationship of CFTR genotype with acquisition of infec-
tion using each of these different definitions as the pri-
mary outcome. Subjects with ‘Minimal’ CFTR function
had a substantially higher risk of acquiring Pa, MPa and
Asp than those with ‘Residual’ CFTR function for any
definitions used (TABLE 4). Thus, use of an alternate
definition of infection does not substantially alter the
Table 2 Overall prevalence of organisms in the U.S. CF Twin and Sibling Study, prevalence of infections in the U.S. CF
Twin and Sibling Study in 2008 and the U.S. CF Foundation Registry [29] in 2008
U.S. CF Twin and Sibling Study Overall U.S. CF Twin and Sibling Study 2008 CF Foundation Registry 2008
Pa 85.4% 46.9% 52.5%
MPa 57.5% Not estimated Not estimated
Asp 40.3% Not estimated Not estimated
Sa 94.3% 48.1% 50.9%
MRSa 39.2% 23.6% 22.6%
Bcc 7.8% 2.1% 2.8%
Atyp 7.3% Not estimated Not estimated
Sm 41.6% 11.6% 12.5%
Ax 19.6% Not estimated Not estimated
Hi 74.2% 15.0% 16.3%
Sp 35.8% Not estimated Not estimated
Ec 19.4% Not estimated Not estimated
Kp 19.8% Not estimated Not estimated
Abbreviations: Pa: Pseudomonas aeruginosa MPa : mucoid Pseudomonas aeruginosa, Asp: Aspergillus fumigatus, Sa: Staphylococcus aureus, MRSa: Methicillin
resistant Staphylococcus aureus, Bcc: Burkholderia cepacia complex, atyp: Atypical mycobacteria, Sm: Stenotrophomonas maltophilia, Ax: Achromobacter xylosoxidans,
Hi: Haemophilus influenzae, Sp: Streptococcus pneumoniae, Ec: Escherichia coli and Kp: Klebsiella pneumoniae.
Table 3 Characteristics of study subjects
’Minimal’ Function ’Residual’ Function p value
Individuals 1218 163
Female 579 (47.5%) 81 (49.7%) 0.605 a
Caucasian 943 (95.5%) 115 (83.9%) <0.001b
Pancreatic Insufficient 1180 (97.8%) 46 (30.3%) <0.001b
Age (yrs) last visit ± SD (range), (n) 15.82 ± 8.60 (0.44-57.31) (1209) 18.59 ± 12.87 (0.54-63.94) (159) 0.133b
Maximal FEV1CF% since last clinic visit, (n) 0.68 ± 0.26 (1111) 0.75 ± 0.25 (145) <0.001
b
Average number of cultures per subject per year ± SD, (n) 3.89 ± 1.92 (1201) 3.93 ± 2.27 (159) 0.530 b
Definition of abbreviations: Maximal FEV1 CF%: CF specific percentile for the maximum forced expiratory volume in one second in the last year of data for the
subject.
a: P-value reported from chi-squared, assumes equal variance in group means.
b: P-value reported from Kruskal-Wallis test due to unequal variances in group means.
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association between predicted CFTR function and acqui-
sition of Pa, MPa or Asp.
CFTR associated risk of infection is influenced by lung
function status at the time of acquisition
Lung function affected the relationship of CFTR and
infection risk and was retained as a significant covariate
in all Cox regression models. To better understand this
relationship, we performed a formal test of interaction
of lung function as a linear covariate and CFTR as a
dichotomous variable. The interaction term of FEV1Be-
foreInfx and CFTR was not significant for each organ-
ism with the exception of Klebsiella which was found to
be highly significant (p-value = 0.008). However, we did
not feel that this adequately represented what we
observed in our data and therefore wanted to confirm
this observation using stratification. Four strata distribu-
ted subjects into roughly equal size groups for each
infecting organism (FEV1BeforeInfx less than the 50
th %
ile, 50-74.9th %ile, 75-89.9th %ile and greater than the
90th %ile) and revealed that the effect of CFTR genotype
upon risk of infection differed depending upon lung
function and the organism involved (TABLE 5). CFTR
genotype confers a significant risk to the acquisition of
8 of 9 organisms for patients in the highest strata of
lung function (i.e. >90th %ile). However, at the lowest
lung function strata (<50th %ile), CFTR genotype signifi-
cantly alters infection risk with only 1 organism (Sa).
These results suggest that protection from lung infec-
tion originally conferred by ‘Residual’ CFTR function is
lost as lung function declines.
Discussion
Pulmonary disease in CF is complicated by patients
acquiring numerous different organisms at different per-
iods of time during his/her lifetime. These organisms
Figure 1 Unadjusted Kaplan-Meier (K-M) plots for 12 of 13 infectious organisms studied. Gray lines represent ‘Minimal’ CFTR function
subjects and black lines represent subjects with ‘Residual’ CFTR function. There are differing numbers of subjects used in each plot due to the
inclusion criteria of having a previous negative culture prior to the first positive culture for the particular organism. Median age differences are
presented for those infections not affected by censoring, otherwise ages corresponding to the point where 25% of the population is affected is
presented. Corresponding t-tests for the unadjusted K-M and Cox proportional hazard ratios with 95% confidence interval adjusted for the
FEV1BeforeInfx and the number of cultures per subject per year are presented. A. Pseudomonas aeruginosa. B. mucoid Pseudomonas aeruginosa.
C. Aspergillus fumigatus. D. Staphylococcus aureus. E. Methicillin-resistant Staphylococcus aureus. F. Stenotrophomas maltophilia. G. Achromobacter
xylosoxidans. H. Atypical mycobacterium. I. Klebsiella pneumoniae. J. Haemophilus influenzae. K. Streptococcus pneumoniae. L. Escherichia coli.
Burkholderia cepacia complex is not presented as few subjects developed this infection and results were limited in interpretation.
Green et al. Respiratory Research 2010, 11:140
http://respiratory-research.com/content/11/1/140
Page 5 of 9
tend to progress from Sa and Hi to Pa. While Pa has
been extensively studied for its relationship with CFTR
mutations, the underlying defect of CF, few studies have
evaluated the effect that CFTR genotype has on infec-
tion risk for other organisms commonly cultured from
CF respiratory tracts. Our study corroborates the finding
that CFTR mutations which permit ‘Residual’ CFTR
function (i.e. class IV or V mutations) are associated
with reduced rates and delayed acquisition of Pa infec-
tion [10,11]. We substantially extend this observation to
include numerous other organisms commonly cultured
from CF patients (mucoid Pa, Staphylococcus aureus,
MRSA, Aspergillus fumigatus, Stenotrophomonas malto-
philia, Achromobacter xylosoxidans, atypical mycobac-
terium and Klebsiella pneumoniae) indicating that
CFTR dysfunction appears to cause a global alteration
in infection resistance in humans. This concept is con-
sistent with recent studies which indicate loss of CFTR
function causes a pervasive defect in resistance to
respiratory infection in pig models of CF [13]. Addition-
ally this study shows that the concept of “mild” CFTR
mutations (often ‘Residual’ function mutations) versus
Table 4 Risk of infection is increased for ‘Minimal’ CFTR function using any definition of infection with Pseudomonas
aeruginosa, mucoid Pseudomonas aeruginosa and Aspergillus fumigatus
Total Positive
(n included in analysis)
’Minimal’ Function
(% of class positive)
’Residual’ Function
(% of class positive)
Adjusted Hazards Ratioa
FirstInfx Pa 318 (436) 278 (79.4%) 40 (46.5%) 3.17 (2.10, 4.78)
ChronInfx Pa 127 (436) 118 (33.7%) 9 (10.5%) 5.47 (2.20, 13.58)
MultiInfx Pa 229 (436) 206 (58.9%) 23 (26.7%) 3.81 (2.32, 6.28)
PersInfx Pa 228 (436) 203 (58.0%) 25 (29.1%) 3.32 (2.00, 5.50)
FirstInfx MPa 492 (919) 453 (56.3%) 39 (33.9%) 2.93 (2.09, 4.09)
ChronInfx MPa 230 (919) 217 (27.0%) 13 (11.3%) 3.85 (2.00, 7.39)
MultiInfx MPa 381 (919) 354 (44.0%) 27 (23.5%) 3.11 (2.09, 4.62)
PersInfx MPa 371 (919) 345 (42.9%) 26 (22.6%) 3.14 (2.06, 4.76)
FirstInfx Asp 451 (1090) 427 (44.0%) 24 (20.0%) 3.77 (2.24, 6.35)
ChronInfx Asp 89 (1090) 88 (9.1%) 1 (0.8%) 18.97 (3.73, 96.43)
MultiInfx Asp 252 (1090) 237 (24.4%) 15 (12.5%) 3.22 (1.73, 5.98)
PersInfx Asp 254 (1090) 243 (25.1%) 11 (9.2%) 4.83 (2.47, 9.46)
Definition of abbreviations: Pa: Pseudomonas aeruginosa, MPa: mucoid Pseudomonas aeruginosa, Asp: Aspergillus fumigatus, FirstInfx: one positive culture for the
organism; MultiInfx: three or more positive cultures for the organism; PersInfx: at least one positive culture for the organism in two of three consecutive years;
ChronInfx: three positive cultures within 6 months each positive culture at least 1 month from the last positive culture.
a: Adjusted for FEV1BeforeInfx and number of cultures.
Table 5 Lung strataa specific hazard ratios for the association of presence of an infection with class mutation status
Multivariate
regressionb
Lung Function <0.50c Lung Function 0.50-0.75c Lung Function 0.75-0.9c Lung Function >0.9c
Pa 3.17 (2.10, 4.78) 1.59 (0.78, 3.24) (n = 81) 3.74 (1.70, 8.22) (n = 112) 4.17 (1.45, 12.0) (n = 110) 4.01 (1.92, 8.36) (n = 133)
MPa 2.93 (2.09, 4.09) 1.59 (0.78, 3.22) (n = 192) 3.80 (2.07, 6.98) (n = 227) 4.23 (2.01, 8.92) (n = 246) 3.83 (2.06, 7.11) (n = 255)
Asp 3.78 (2.24, 6.37) 2.85 (0.77, 10.63) (n = 250) 10.22 (3.25, 32.21) (n = 282) 4.51 (1.46, 13.92) (n =
269)
2.82 (1.34, 5.93) (n = 289)
Sa 1.70 (1.13, 2.53) 3.41 (1.43, 8.16) (n = 74) 1.05 (0.54, 2.03) (n = 83) 0.90 (0.40, 2.06) (n = 66) 1.94 (1.02, 3.70) (n = 64)
MRSa 2.27 (1.37, 3.75) 2.04 (0.71, 5.87) (n = 237) 2.06 (0.84, 5.05) (n = 262) 1.80 (0.76, 4.30) (n = 260) 3.40 (1.41, 8.21) (n = 273)
Atyp 2.33 (1.06, 5.12) 2.12 (0.27, 16.66) (n = 265) 5.41 (0.42, 70.41) (n = 294) 1.40 (0.52, 3.78) (n = 292) 2.47 (1.06, 5.72) (n = 303)
Sm 3.27 (1.95, 5.47) 2.70 (0.88, 8.31) (n = 229) 3.62 (1.52, 8.62) (n = 257) 2.45 (1.12, 5.33) (n = 260) 3.64 (1.31, 10.13) (n = 247)
Ax 2.57 (1.25, 5.26) 1.94 (0.42, 9.05) (n = 252) 8.41 (1.83, 38.58) (n = 282) 2.07 (0.59, 7.30) (n = 275) 1.93 (0.64, 5.82) (n = 293)
Kp 3.47 (1.27, 9.48) 0.28 (0.07, 1.06) (n = 233) 7.87 e15 (2.30 e15, 2.69
e16) (n = 250)
7.55 e15 (2.60 e15, 2.19
e16) (n = 247)
4.73 (1.15, 19.43) (n = 258)
Definition of abbreviations: Pa: Pseudomonas aeruginosa MPa : mucoid Pseudomonas aeruginosa, Asp: Aspergillus fumigatus, Sa: Staphylococcus aureus, MRSa:
Methicillin resistant Staphylococcus aureus, atyp: Atypical mycobacteria, Sm: Stenotrophomonas maltophilia, Ax: Achromobacter xylosoxidans, Kp: Klebsiella
pneumoniae.
a: Individual subjects may be in different strata for each infection as the value for the lung function variable reflects the maximal value in the year preceding
acquisition of each of the organisms.
b: Cox regression adjusted for FEV1BeforeInfx and number of cultures per year for the subject; comparing ‘Residual’ function to ‘Minimal’ function.
c: Stratified Cox regression adjusted for number of cultures per year for the subject; comparing ‘Residual’ function to ‘Minimal’ function in each stratum.
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“severe” CFTR mutations (often ‘Minimal’ function
mutations) may extend beyond pancreatic status to
other features such as lung infection. Furthermore, we
show that the association between CFTR genotype and
respiratory infection has a complex relationship with the
severity of lung disease. CFTR mutations that permit
‘Residual’ function reduce the risk of infection with mul-
tiple organisms in patients with mild lung dysfunction
evidenced by near normal forced expiratory volumes.
However, in patients with compromised lung function,
the protective effect of ‘Residual’ CFTR function is lost
for most of the organisms studied.
To date, studies on the role of CFTR as a risk factor for
acquisition of infectious organisms have concentrated on
the most common mutation, F508del. A few studies have
assessed the role of the CFTR genotype beyond the classi-
fication of F508del homozygotes versus all others. One
study found that mis-sense and splice mutations pre-
dicted to confer “mild” effect were associated with lower
rates and later acquisition of Pa infection [9]. However,
mis-sense and splice-site mutations have different effects
upon CFTR function; the former being associated with
protein formation (and possible residual function) while
the latter is usually associated with no protein being
made (and no residual function) [24]. Two subsequent
studies [10,11] demonstrated that stratifying CFTR muta-
tions by putative function was associated with lower rates
of Pa infection. One of these studies [11] attempted to
associate CFTR mutation class with infection risk for
other organisms but failed to show a reliable association.
One reason this current study found an association of
CFTR genotype with multiple respiratory pathogens may
be due to the increased power afforded by a larger sam-
ple size when subjects with class IV or V mutations are
combined (as opposed to assessing each mutation class
separately [11]). Alternatively, non-genetic factors may
play a role as the prior study was performed in Europe as
opposed to the current U.S. study.
Furthermore, the role of CFTR in the acquisition of
lung infection has been debated. One possibility is that
CFTR on epithelial cell membranes binds organisms
directly by recognizing the lipopolysaccharide coat of Pa
[25] thus allowing endocytosis and eventual destruction
of Pa. Loss of this bacterial clearance process due to
mutations that do not permit residual CFTR function
(class I, II or III) is postulated to underlie the chronic
infectious state associated with Pa [26]. This however
does not fully explain the relationship observed for
CFTR and other organisms. A second hypothesis posits
that defective clearance of infecting organisms due to
altered properties of airway surface liquid and innate
defense caused by CFTR dysfunction [27,28]. In this sce-
nario, our results might suggest that mutations causing
a moderate loss of CF function lead to less severe
changes in epithelial barriers to infection and conse-
quently lower rate of infection with a number of organ-
isms commonly found in the CF lung. Regardless of
mechanism, the findings of this study indicate that
reduced CFTR function leads to a global disruption of
infection control and acquisition.
We have to acknowledge that there are several weak-
nesses in this study. First, the study was retrospective and
patients were enrolled on the basis of being diagnosed
with CF and having a sibling diagnosed with CF. This
inclusion criterion may have skewed our population as
survival of both siblings until entry in our study was
required. To assess for a possible bias toward milder CF
patients who may have a lower rate of respiratory infec-
tion, we compared our data to the general U.S. CF popu-
lation in the CFF registry and found rates of infection in
this study to be similar to the unrelated U.S. CF popula-
tion (TABLE 2). Another weakness is that we did not
apply a correction for age of diagnosis of CF as this event
may have been precipitated by a positive respiratory
culture. To address this shortcoming, we ensured that
subjects had at least one negative respiratory culture for
the organism being studied prior to entry into the analy-
sis thereby excluding individuals who were infected at
the time of CF diagnosis.
Strengths of this study include sample size, the con-
servative use of alternative definitions of infection and
assessment of lung function prior to the acquisition of
the organism. Using a mean survival time of 5 years for
the control group (‘Minimal’ function), 5 years for
accrual of all subjects, 10 years of follow-up time and
80% power, we had an adequate sample size to detect a
hazard ratio (HR) of 1.3. As shown in FIGURE 1, organ-
isms that demonstrated a significant correlation with
CFTR function had HRs that considerably exceeded this
threshold. While our main outcome measure was the
initial acquisition of an organism, we also stratified
patients using 3 other definitions for infection. As highly
similar results were obtained when using either of these
definitions, we conclude that our results are indepen-
dent of the criteria used to assign infection status. Inclu-
sion of additional definitions of infection also helped
overcome the issue of using a single throat culture (if
that was the only culture information for a subject) to
determine infection status since throat cultures are
known to have poor negative predictive value. By
including criteria which require assessment of multiple
cultures, correct classification of subjects is more
assured. Finally, by assessing lung function prior to the
acquisition of the infectious organism analyzed, we were
able to evaluate whether the association between pre-
dicted CFTR function and infection status was depen-
dent on the severity of lung disease around the time of
first infection.
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Conclusions
In conclusion, genotypes predicting ‘Minimal’ CFTR
function are associated with increased risk and earlier
age of infection by multiple organisms. For those with
decreased lung function, ‘Residual’ CFTR genotype no
longer provides a protective effect on infection risk.
These observations suggest that 1) adjustment for CFTR
functional genotype may be necessary in genetic modi-
fier studies of infection, 2) monitoring infection status
in patients with mild lung disease, especially children,
could be an outcome measure for therapies that aug-
ment CFTR function and 3) augmentation of CFTR
function may not reduce the risk of infection in patients
with severe lung disease.
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